Tianfeng Securities released a research report on April 17 stating that it gave Rhine Biotech (002166.SZ) a purchase rating. The main reasons for the rating include: 1) downstream customers are under pressure to inventory the company's performance; 2) the signing of a new 5-year cooperation agreement with the customer, stevia production capacity will be released in 2024, and the natural sweetener business can be expected to continue to grow; 3) the cumulative target revenue amount of this agreement is US$840 million, and the minimum cumulative target revenue amount is US$680 million; 4) the development of the industrial hemp business falls short of expectations, and the market is expected to improve rapidly in the future. (Mainichi Keizai Shimbun)
天风证券4月17日发布研报称，给予莱茵生物（002166.SZ）买入评级。评级理由主要包括：1）下游客户去库存公司业绩承压，23Q4曙光已现；2）与客户签订5年合作新协议，2024年甜叶菊产能释放，天然甜味剂业务持续增长可期；3）本协议累计目标收入金额为8.4亿美元，最低累计目标收入金额为6.8亿美元；4）工业大麻业务发展不及预期，市场未来有望实现快速提升。（每日经济新闻）
Tianfeng Securities released a research report on April 17 stating that it gave Rhine Biotech (002166.SZ) a purchase rating. The main reasons for the rating include: 1) downstream customers are under pressure to inventory the company's performance; 2) the
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated